Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade DOI: 10.1158/2159-8290.CD-25-1616
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial DOI: 10.1038/s41467-026-72735-8
Cell-free DNA methylome and fragmentome analysis for relapse monitoring of Ewing sarcoma DOI: 10.1038/s44321-026-00396-7
Overall survival for bevacizumab therapy in metastatic colorectal cancer: an updated analysis of the TRAVASTIN study DOI: 10.1016/j.clcc.2025.11.001
Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis DOI: 10.1158/2159-8290.CD-24-1224 Abstract
EORTC 1417 – REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer DOI: 10.1016/j.ejca.2025.116059
UpSMART: five years of digital innovation in cancer clinical research—achievements, challenges, and recommendations DOI: 10.3389/fdgth.2025.1708067
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium DOI: 10.1093/neuonc/noaf140
